Izotropic (IZO) AI Stock Analysis

• Market Cap: C$23.92M
• Dividend Yield: N/A
• Average Volume (3M): 51.69K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.81
• Revenue Growth: N/A
• EPS Growth: 11.68%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 64,653,680
• 10 Day Avg. Volume: 31,774
• 30 Day Avg. Volume: 51,689
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

Izotropic's overall stock score is low, primarily due to significant financial challenges, including consistent revenue shortfalls, negative income, and unsustainable cash flows. Despite some positive technical indicators and promising corporate events suggesting potential future growth, the company's current financial instability and negative valuation metrics weigh heavily on its stock score.

Izotropic Business Overview & Revenue Model

Company Description

Izotropic Corporation (IZO) is a medical technology company focused on developing and commercializing diagnostic products in the healthcare sector. The company's flagship product is the IzoView breast CT imaging system, designed to improve breast cancer detection and diagnosis by providing high-resolution 3D images of breast tissue. Through innovative imaging solutions, Izotropic aims to enhance diagnostic accuracy and patient outcomes.

How the Company Makes Money

Izotropic Corporation primarily generates revenue through the sale and distribution of its breast CT imaging systems to healthcare providers, including hospitals and diagnostic centers. The company may also engage in service contracts, providing maintenance and support for its imaging systems. Additionally, Izotropic could potentially earn revenue through partnerships or collaborations with research institutions and healthcare organizations, contributing to the development and enhancement of imaging technologies. However, specific details regarding partnerships or additional revenue streams are not available.

Izotropic Financial Statement Overview

Summary

Izotropic is facing substantial financial headwinds, characterized by consistent revenue shortfalls, significant operating losses, and a weak balance sheet. The firm exhibits unsustainable cash flow dynamics, relying heavily on external financing to sustain operations. A strategic overhaul is imperative to improve financial health and operational efficiency.

Income Statement

The income statement shows significant challenges, with consistent zero revenue and negative net income over the periods analyzed. The company is unable to achieve profitability, with EBIT and EBITDA margins being negative, reflecting operational inefficiencies and high operating expenses relative to nonexistent revenue.

Balance Sheet

The balance sheet indicates a precarious financial position, marked by negative stockholders' equity and high levels of debt, leading to a concerning debt-to-equity ratio. The company's liabilities exceed its assets, indicating potential solvency risks and a need for substantial financial restructuring.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, underscoring cash burn and insufficient cash generation from operations. Despite some financing inflows, the company's reliance on external funding is unsustainable, highlighting financial instability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-27.37K	-48.90K	-59.07K	-30.88K	-6.87K	-1.63K
EBITDA	-1.74M	-2.14M	-1.60M	-5.33M	-6.63M	-4.97M
Net Income	-2.04M	-3.14M	-1.56M	-5.66M	-6.67M	-4.98M
Balance Sheet
Total Assets	382.09K	414.73K	232.38K	442.11K	2.27M	4.69M
Cash, Cash Equivalents and Short-Term Investments	220.78K	274.11K	38.60K	165.69K	1.86M	4.06M
Total Debt	2.03M	2.76M	2.06M	2.14M	2.03M	0.00
Total Liabilities	5.16M	5.27M	4.08M	3.52M	2.64M	169.28K
Stockholders Equity	-4.78M	-4.86M	-3.85M	-3.07M	-374.59K	4.52M
Cash Flow
Free Cash Flow	-423.36K	-637.37K	-593.57K	-3.30M	-4.79M	-3.08M
Operating Cash Flow	-422.22K	-636.23K	-593.57K	-3.27M	-4.76M	-3.08M
Investing Cash Flow	-1.14K	-1.14K	0.00	-36.18K	-24.23K	0.00
Financing Cash Flow	567.34K	872.78K	468.18K	1.61M	2.58M	6.53M

Izotropic Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Positive. The current price of 0.37 is below the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.33, and above the 200-day MA of 0.28, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 54.27 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:IZO.

Izotropic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	47 Neutral	C$37.83M	―	-504.79%	―	-4.26%	4.32%
SONA	40 Underperform	C$68.47M	―	-2846.90%	―	―	10.97%
IZO	37 Underperform	C$23.92M	―	40.96%	―	―	11.68%
TELO	28 Underperform	C$6.50M	―	-303.19%	―	―	23.32%

Izotropic Corporate Events

Izotropic Enhances Global Outreach and Amends Financial Agreements

Izotropic Corporation has engaged JG Global Communications, led by James Gagnon, as its International Communications Consultant to enhance global outreach and investor relations, particularly in Asia and Europe. The company has also issued stock options and restricted share units to key personnel to align their interests with shareholders and amended a promissory note with its primary lender, reflecting a new loan balance and issuing additional bonus warrants.

Izotropic Advances FDA Discussions for Breast Cancer Imaging System

Izotropic Corporation has completed a pre-submission meeting with the FDA regarding its IzoView Breast CT Imaging System, focusing on its use for breast cancer screening. The meeting facilitated a collaborative exchange, addressing key topics such as clinical study protocol, benefits versus risks of contrast-enhancement, and the management of breast cancers detected by IzoView but not visible on other imaging methods. The discussions are expected to advance the regulatory strategy for the IzoView system, potentially enhancing the company’s positioning in the breast cancer imaging market.

Izotropic to Highlight IzoView’s Market Potential at Investor Conference

Izotropic Corporation announced that its CEO, Robert Thast, will present at the Life Sciences Virtual Investor Conference, discussing the competitive advantage of their IzoView Breast CT system in the growing breast imaging market. The global breast imaging device market is projected to grow significantly, positioning Izotropic to capitalize on increased demand driven by rising breast cancer rates and regulatory changes, making this a crucial opportunity for investors to engage with the company.

Izotropic Raises $455,000 in Private Placement to Bolster Operations

Izotropic Corporation announced the completion of a non-brokered private placement financing, raising $455,000 through the issuance of 3,033,333 units at $0.15 per unit. The funds are earmarked for general and administrative purposes, and the addition of two strategic investors indicates potential future collaboration, which could impact the company’s operations and industry positioning.

Izotropic Launches Private Placement to Raise $360,000

Izotropic Corporation announced a non-brokered private placement financing to raise up to $360,000 by issuing 2,400,000 units at $0.15 each. This funding will be used for general working capital, and the offering’s completion is contingent upon regulatory approvals. The securities will not be registered under the U.S. Securities Act and won’t be available for sale in the United States.